Literature DB >> 30734904

Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Takumi Hoshino1, Satoru Takada2, Nahoko Hatsumi2, Toru Sakura2.   

Abstract

Primary graft failure (PGF) is a lethal complication that occurs early after allogeneic stem cell transplantation (allo-SCT). Cord blood transplantation (CBT) is a potential re-transplantation option. Total body irradiation (TBI) is often incorporated into the pre-salvage CBT conditioning regimen following PGF; however, patients experiencing PGF are not always amenable to TBI, and non-TBI regimens for salvage CBT should be established. Here, we report five patients with hematologic malignancies who received salvage CBT for PGF following a non-TBI regimen using fludarabine (Flu), melphalan (Mel), and low-dose anti-thymocyte globulin (ATG). The median intervals between the failed allo-SCT and salvage CBT, as well as between the diagnosis of PGF and salvage CBT, were 37 days and 8 days, respectively. The median neutrophil recovery period was 21 days (range 18-21 days). Four of five patients achieved neutrophil engraftment following salvage CBT; all four exhibited sustained engraftment with complete donor chimerism. Three of the five patients were alive after a median follow-up time of 907 days (range 315-909 days) post-salvage CBT; two patients died of causes unrelated to recurrence. These data suggest that CBT following the non-TBI regimen described here is feasible in patients with PGF.

Entities:  

Keywords:  Anti-thymocyte globulin; Cord blood transplantation; Primary graft failure; Salvage; Total body irradiation

Mesh:

Substances:

Year:  2019        PMID: 30734904     DOI: 10.1007/s12185-019-02610-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  40 in total

1.  Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation.

Authors:  P Guardiola; M Kuentz; F Garban; D Blaise; J Reiffers; M Attal; A Buzyn; B Lioure; P Bordigoni; N Fegueux; M L Tanguy; J P Vernant; E Gluckman; G Socié
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

Review 2.  Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation.

Authors:  Christian Thiede; Martin Bornhäuser; Gerhard Ehninger
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

3.  Cord-blood transplants from unrelated donors in Hurler's syndrome.

Authors:  George Fujisaki; Masahiro Kami; Yukiko Kishi
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

4.  Second cord blood transplantation (CBT) with reduced-intensity conditioning for graft failure after the first CBT for AML.

Authors:  C Ohwada; C Nakaseko; S Ozawa; M Takeuchi; K Shono; M Koizumi; E Sakaida; R Cho; Y Saito; M Nishimura
Journal:  Bone Marrow Transplant       Date:  2004-12       Impact factor: 5.483

5.  Severe regimen-related toxicity of second transplantation for graft failure following reduced-intensity cord blood transplantation in an adult patient.

Authors:  K Shimada; H Narimatsu; Y Morishita; A Kohno; S Saito; Y Kato
Journal:  Bone Marrow Transplant       Date:  2006-04       Impact factor: 5.483

6.  Graft failure following reduced-intensity cord blood transplantation for adult patients.

Authors:  Hiroto Narimatsu; Masahiro Kami; Shigesaburo Miyakoshi; Naoko Murashige; Koichiro Yuji; Tamae Hamaki; Kazuhiro Masuoka; Eiji Kusumi; Yukiko Kishi; Tomoko Matsumura; Atsushi Wake; Shinichi Morinaga; Yoshinobu Kanda; Shuichi Taniguchi
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

7.  Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies.

Authors:  G F Sanz; S Saavedra; D Planelles; L Senent; J Cervera; E Barragán; C Jiménez; L Larrea; G Martín; J Martínez; I Jarque; F Moscardó; G Plumé; R Andreu; A I Regadera; I García; S Mollá; P Solves; J de La Rubia; P Bolufer; L Benlloch; M A Soler; M L Marty; M A Sanz
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

8.  Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.

Authors:  Hakumei Oh; Fausto R Loberiza; Mei-jie Zhang; Olle Ringdén; Hideki Akiyama; Takayoshi Asai; Shuichi Miyawaki; Shinichiro Okamoto; Mary M Horowitz; Joseph H Antin; Asad Bashey; Jennifer M Bird; Matthew H Carabasi; Joseph W Fay; Robert Peter Gale; Roger H Giller; John M Goldman; Gregory A Hale; Richard E Harris; Jean Henslee-Downey; Hans-Jochem Kolb; Mark R Litzow; Philip L McCarthy; Steven M Neudorf; Derek S Serna; Gerard Socié; Pierre Tiberghien; A John Barrett
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

9.  Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.

Authors:  E Kusumi; M Kami; K Yuji; T Hamaki; N Murashige; A Hori; R Kojima; Y Kishi; S-W Kim; J Ueyama; S Miyakoshi; R Tanosaki; S Morinaga; S Mori; Y Heike; Y Muto; S Masuo; S Taniguchi; Y Takaue
Journal:  Bone Marrow Transplant       Date:  2004-04       Impact factor: 5.483

10.  Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.

Authors:  Susan L Staba; Maria L Escolar; Michele Poe; Young Kim; Paul L Martin; Paul Szabolcs; June Allison-Thacker; Susan Wood; David A Wenger; Pablo Rubinstein; John J Hopwood; William Krivit; Joanne Kurtzberg
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

View more
  1 in total

1.  Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.

Authors:  Olle Ringdén; Mats Remberger; Johan Törlén; Sigrun Finnbogadottir; Britt-Marie Svahn; Behnam Sadeghi
Journal:  Int J Hematol       Date:  2021-02-05       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.